Myklebust, E, Schjesvold, F, Frigessi, A, Leder, K, Foo, J, and Köhn-Luque, A. Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasone. Retrieved from https://par.nsf.gov/biblio/10615265.
Myklebust, E, Schjesvold, F, Frigessi, A, Leder, K, Foo, J, & Köhn-Luque, A. Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasone. Retrieved from https://par.nsf.gov/biblio/10615265.
Myklebust, E, Schjesvold, F, Frigessi, A, Leder, K, Foo, J, and Köhn-Luque, A.
"Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasone". Country unknown/Code not available: medrxiv. https://par.nsf.gov/biblio/10615265.
@article{osti_10615265,
place = {Country unknown/Code not available},
title = {Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasone},
url = {https://par.nsf.gov/biblio/10615265},
abstractNote = {},
journal = {},
publisher = {medrxiv},
author = {Myklebust, E and Schjesvold, F and Frigessi, A and Leder, K and Foo, J and Köhn-Luque, A},
}
Warning: Leaving National Science Foundation Website
You are now leaving the National Science Foundation website to go to a non-government website.
Website:
NSF takes no responsibility for and exercises no control over the views expressed or the accuracy of
the information contained on this site. Also be aware that NSF's privacy policy does not apply to this site.